Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Genprex Inc. GNPX

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

Posted on June 2, 2023 by MissionIR

Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Posted on May 17, 2023 by MissionIR

Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments, announced last month that its research collaborators presented positive preclinical data for the NPRL2 gene, which … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

Posted on May 10, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

Posted on May 6, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

Posted on May 5, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Posted on May 4, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

Posted on April 21, 2021 by MissionIR

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

Posted on April 20, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Posted on April 12, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

Posted on April 5, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment